AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead psychedelic therapy candidate, bretisilocin, for up to $1.2 billion, consolidating its presence in neuroscience drug development. This acquisition follows prior collaborations, including a $65 million upfront payment and development milestones with potential for substantial royalties. The move reflects AbbVie's strategic pivot towards novel psychiatric disorder treatments amid recent Phase 2 successes of the compound. Gilgamesh plans to spin out its remaining pipeline into a new company, focusing its resources on this promising psychedelic program.